Tomi Environmental Solutions Signs Merger LOI with Carbonium Core
Tomi Environmental Solutions announced that it has executed a non-binding letter of intent to merge with Carbonium Core, a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies. A to-be-created wholly-owned subsidiary of the company will merge with Carbonium Core, such that Carbonium Core will become a wholly owned subsidiary of the company. The former Carbonium Core stockholders will receive, as merger consideration, shares of Tomi common stock equal to 19.99% of the company's outstanding shares of common stock as of immediately prior to the merger and shares of a newly created series of preferred stock of the company, convert into Tomi common stock upon stockholder approval. With the shares of TOMI common stock and the newly created preferred stock, the enterprise valuation of Carbonium Core will be in the amount of $120M as of the date of the LOI, subject to further due diligence. The merger is subject to execution of definitive agreements and customary closing conditions. Aggregate consideration to be paid by Tomi to Carbonium Core consists of shares of common stock and a newly created series of preferred stock of Tomi with an aggregate stated and liquidation value of $120M. An independent valuation analysis conducted in November 2025 valued Carbonium's business at $990M. The preferred stock will be convertible into shares of Tomi common stock subject to receipt of stockholder approval in accordance with the rules of the Nasdaq Stock Market. The preferred stock will not carry voting rights. The parties currently expect to negotiate and execute definitive agreements for the proposed transaction during the second quarter 2026, subject to extension by mutual agreement. Carbonium Core has agreed to a 45-day exclusivity period during which it will not solicit or engage in discussions regarding alternative transactions. Completion of the proposed transaction remains subject to satisfactory due diligence, execution of definitive agreements, receipt of required approvals, and other customary closing conditions. There can be no assurance that definitive agreements will be executed, that the proposed transaction will be consummated on the terms described herein or at all, or as to the timing or final terms of any transaction. Either party may terminate the LOI under customary circumstances, including failure to complete due diligence or by mutual written consent, without break-up fees.
Trade with 70% Backtested Accuracy
Analyst Views on TOMZ

No data
About TOMZ
About the author

- Significant Revenue Growth: In Q1 2026, TOMI reported a 5% year-over-year revenue increase and a 67% sequential rise, with applicator sales surpassing total sales for all of 2025, indicating strong market demand and product acceptance.
- Order and Service Expansion: By the end of Q1 2026, TOMI's backlog grew from $1.6 million at the end of 2025 to $2.2 million, alongside receiving 440,000 annual purchase orders for recurring decontamination services, reflecting a robust customer base in the medical technology sector.
- International Market Authorizations: The company secured product authorizations in the UK, Netherlands, Germany, Belgium, Denmark, and Hungary during Q1 2026, accelerating its international expansion and enhancing its global market share.
- Strategic Merger Plans: TOMI intends to merge with Carbonium Core, Inc., with an enterprise valuation of $120 million under the LOI, aiming to finalize definitive agreements by May 30, 2026, showcasing its proactive strategy to expand operations and strengthen market competitiveness.
- Surge in Demand: The ongoing virus outbreaks on cruise ships and public facilities have rapidly increased the demand for TOMI's SteraMist technology, which is expected to create long-term growth opportunities for the company, particularly in high-density travel environments.
- Significant Technological Advantage: SteraMist employs ionized hydrogen peroxide technology to rapidly disinfect air and surfaces while minimizing downtime, having been validated in high-risk sectors such as healthcare, pharmaceuticals, and transportation, highlighting its critical role in infection control.
- Accelerated Industry Transformation: As consumer awareness of sanitation standards intensifies, travel operators may be compelled to market advanced disinfection measures as a competitive differentiator, thereby enhancing customer trust and protecting occupancy rates.
- Clear Strategic Positioning: TOMI's unique positioning in infection prevention, hospitality safety, and biosecurity infrastructure makes it a potential leader in the large-scale disinfection market amid heightened global public health concerns.
- Technology Approval Expansion: TOMI's Binary Ionization Technology has received formal approval in Belgium, Denmark, Germany, and Hungary, marking an expansion of the company's authorizations in the EU and enhancing its competitive position in the medical, commercial, and industrial sectors.
- Accelerated Market Access: Under the EU's Biocidal Products Regulation, TOMI's products can achieve mutual recognition in multiple countries, expected to expedite market entry in Austria, France, Ireland, and others, reducing the time and costs associated with repeated authorizations.
- Strategic Growth Potential: COO E.J. Shane stated that this expansion not only reflects the company's commitment to effective disinfection solutions but also lays the groundwork for future sales growth in the European market, anticipated to deliver greater value to shareholders.
- Wide Product Application: TOMI's Binary Ionization Technology is widely utilized in various commercial structures, including hospitals, schools, and hotels, demonstrating its adaptability and growth potential across diverse markets.
- Merger Overview: TOMI Environmental Solutions has announced a non-binding letter of intent to acquire Carbonium Core for an all-stock transaction valued at $120 million, with a targeted closing in Q2 2026, indicating a strategic move into the nuclear-grade graphite market.
- Stock Issuance Details: The transaction will involve issuing new common stock and Series B Convertible Preferred Stock, convertible at $1.00 per share, subject to Nasdaq shareholder approval, which will impact the company's equity structure and potentially enhance market confidence.
- Market Potential Analysis: This merger aims to tap into a multi-billion-dollar market driven by U.S. supply chain reshoring and next-generation nuclear deployment, demonstrating TOMI's proactive approach to growth opportunities in advanced materials.
- Executive Presentation: The CEOs of TOMI and Carbonium Core will present at Wall Street Reporter's NEXT SUPER STOCK livestream event, enhancing the company's visibility among investors and providing a platform for direct engagement with potential stakeholders.








